
Evidence analysis
Quarterly System Demo – Q4 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 December 2026, 09:00 (CET) to 10 December 2026, 12:30 (CET)
European Medicines Agency Quarterly System Demo – Q4 2026: An Evidence Analysis On 10 December 2026, the European Medicines Agency (EMA) held its 20th Quarterly System Demo, marking the final event of the year for its Agile Network…
Read →
Evidence analysis
Country report: ECDC Public Health Emergency Preparedness Assessment for Norway, 2025 – Under Article 8 of the Regulation (EU) 2022/2371
Evidence Dossier: Norway’s Public Health Emergency Preparedness Assessment 2025 What is established In 2025, the European Centre for Disease Prevention and Control (ECDC) conducted a comprehensive Public Health Emergency Preparedness Assessment for Norway. This assessment was part of…
Read →
Evidence analysis
Egypt: Prominent Journalist Lina Attalah Detained
What is established On October 27, 2026, Lina Attalah, editor-in-chief of the independent Egyptian news platform Mada Masr, was convicted by the New Cairo Misdemeanor Court. The charges brought against her resulted in a fine of 3 million…
Read →
Evidence analysis
‘Bought-off, corrupt’: Argentine president attacks ICIJ member Hugo Alconada Mon
What is established In late October 2026, Argentine President Javier Milei publicly insulted and threatened several journalists, including Hugo Alconada Mon, a veteran investigative reporter and member of the International Consortium of Investigative Journalists (ICIJ). This incident followed…
Read →
Evidence analysis
Cost-effectiveness of recommended interventions for managing low back pain: A systematic review
What is established Low back pain (LBP) is recognized as the leading cause of disability worldwide, posing significant health, social, and economic challenges. It affects millions globally and leads to considerable costs in healthcare services, lost productivity, and…
Read →
Evidence analysis
Co-exposure to planned power outages and wildfire PM<sub>2.5</sub> and acute healthcare utilization in California: A time-stratified case-crossover study
Health Impacts of Planned Power Outages and Wildfire Smoke in California: Evidence from a Case-Crossover Study Power shutoffs by electric utilities, intended to prevent wildfires in California, are a growing strategy amid climate-driven wildfire risk. While aimed at…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 18, Status: Authorised
Evidence Dossier: Vocabria (Cabotegravir) – HIV Treatment What is established Vocabria, containing the active substance cabotegravir, is an anti-HIV medication authorized in the European Union since December 2020. It is prescribed alongside rilpivirine to treat adults and adolescents…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 17, Status: Authorised
What is established Idacio is a biosimilar medicine containing the active substance adalimumab, authorized for use in the European Union since April 2019. Adalimumab is a monoclonal antibody that targets tumor necrosis factor (TNF), a key molecule involved…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Hemlibra, emicizumab, Date of authorisation: 23/02/2018, Revision: 21, Status: Authorised
Evidence Dossier: Hemlibra for Hemophilia A – European Medicines Agency Assessment What is established Hemlibra (emicizumab) is a medicine authorised in the European Union for preventing or reducing bleeding episodes in patients with haemophilia A, an inherited bleeding…
Read →
Evidence analysis
Breast cancer treatment: When less is more
Breast Cancer Treatment: When Less is More – Evidence Dossier Source: PLOS Medicine, October 26, 2026, article by Katarzyna Starowicz on behalf of the PLOS Medicine Staff Editors What is Established Breast cancer mortality has declined annually by…
Read →